Trial Profile
A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding everolimus to letrozole as preoperative therapy of primary breast cancer in postmenopausal women
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Letrozole
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Apr 2009 Primary endpoint results published in Journal of Clinical Oncology 27
- 03 Jun 2008 Results reported at ASCO 2008.
- 18 Dec 2007 Status changed from recruiting to completed